JACC: Cardiovascular Interventions
Volume 2, Issue 3, March 2009 DOI: 10.1016/j.jcin.2008.12.009
PDF Article
Clinical Research

TAXUS Liberté Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus
Results From the TAXUS ATLAS Program

Ehtisham Mahmud, John A. Ormiston, Mark A. Turco, Jeffrey J. Popma, Neil J. Weissman, Charles D. O'Shaughnessy, Tift Mann, Jack J. Hall, Thomas F. McGarry, Louis A. Cannon, Mark W.I. Webster, Lazar Mandinov and Donald S. Baim

Figure 2

Figure 2
Figure 2

Cumulative Frequency Distribution of 9-Month In-Stent and In-Segment Late Loss by Quantitative Coronary Angiography

Subjects with and without diabetes treated with the TAXUS Liberté Stent in the TAXUS ATLAS studies. (A) In-stent; and (B) in-segment. Intent-to-treat, angiographic subset (n = 1,201; diabetic: 334; nondiabetic: 867).

  View article

Advertisement